Buprenorphine - Hikma Pharmaceuticals USA Inc.
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Effective date
- 2025-02-21
- Label type
- RISK EVALUATION & MITIGATION STRATEGIES
- Version
- 6
- Source
- full-release
- Hydrated at
- 2026-06-04 22:50:42
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
This REMS applies to BTODs indicated for the treatment of opioid dependence. This REMS does not apply to buprenorphine-containing products that are dispensed to patients undergoing treatment through an Opioid Treatment Program under 42 CFR Part 8.
I. Administrative Information
Risk: accidental overdose, misuse, and abuse
Initial Shared System REMS Approval: 02/2013
Most Recent REMS Update: 02/2025
II. REMS Goals
The goals of the BTOD REMS are to:
- Mitigate the risks of accidental overdose, misuse, and abuse
- Inform prescribers, pharmacists, and patients of the serious risks associated with BTODs
III. REMS Requirements
REMS Participant Requirements
BTOD Applicants must ensure that prescribers and patients comply with the following requirements:
1. Prescribers who prescribe or dispense BTODs must:
Before treatment initiation (first dose) |
|
During treatment; at the first visit following induction |
|
During treatment; at visits scheduled at intervals commensurate with patient stability |
|
2. Patients who are prescribed BTODs:
Before treatment initiation |
|
During treatment; at time intervals determined by your prescriber |
|
REMS Applicant Requirements
To inform healthcare providers about the REMS and the risks and safe use of BTODs, BTOD Applicants must disseminate REMS communication materials according to the table below:
Target Audience | Communication Materials & Dissemination Plan |
All healthcare providers who prescribe BTODs for the treatment of opioid dependence | REMS Letter: Dear Prescriber Letter with attachments, Important Drug Safety Information for Prescribers and Appropriate Use Checklist.
|
All new healthcare providers who prescribe BTODs for the treatment of opioid dependence since the last dissemination | REMS Letter: Dear Prescriber Letter with attachments, Important Drug Safety Information for Prescribers and Appropriate Use Checklist
|
All retail pharmacies authorized by the DEA to handle schedule III controlled substances | REMS Letter: Dear Pharmacist Letter with attachment, Important Drug Safety Information for Pharmacists.
|
To support REMS operations, BTOD Applicants must:
- Establish and maintain a REMS website,
www.btodrems.com. The REMS website must include the option to print the Prescribing Information, Medication Guides, and REMS materials. All product websites for consumers and healthcare providers must include prominent REMS-specific links to the REMS website. The REMS website must not link back to the promotional product websites. - Make the REMS website fully operational and all REMS materials available through the website, BTOD REMS specialists, and call center within 60 calendar days of REMS modification.
- Establish and maintain a REMS call center at 1-855-223-3922.
- Ensure that the Medication Guide is made available for dispensing with each BTOD prescription.
To ensure REMS participants’ compliance with the REMS, BTOD Applicants must:
- Maintain adequate records to demonstrate that REMS requirements have been met, including, but not limited to, records of mailings and outbound calls. These records must be readily available for FDA inspections.
- Establish and maintain a plan for addressing noncompliance with REMS requirements.
- Monitor compliance with the prescriber requirements to document prescribing and dispensing with documentation of safe use conditions through surveys of patients and prescribers, evaluations of health care utilization databases, and ongoing surveillance (sources including, but not limited to, internet, national databases, and surveys conducted at substance abuse treatment programs).
- On a monthly basis, identify and attempt to contact a random sample of prescribers who were sent educational materials via email or mail during the previous month to create awareness of the REMS, confirm that REMS materials have been received, and confirm understanding of the BTOD REMS requirements.
- Provide a copy of the REMS materials to prescribers who request or did not receive the REMS materials.
- Provide additional follow-up information about the BTOD REMS.
- Option I: a live online meeting to review BTOD REMS requirements
- Option II: a field visit to review BTOD REMS requirements
- Provide additional follow-up information about the BTOD REMS.
- Take reasonable steps to improve operations of and compliance with the requirements in the BTOD REMS based on monitoring and evaluation of the BTOD REMS.
IV. REMS Assessment Timetable
BTOD NDA Applicants must submit REMS Assessments at 12 months from August 30, 2021, and annually thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment. BTOD NDA Applicants must submit each assessment so that it will be received by the FDA on or before the due date.
V. REMS Materials
The following materials are part of the BTOD REMS:
Training and Education Materials
Patient
- Medication Guide (available at
btodrems.com)
Patient Care Form
- Appropriate Use Checklist
Communication Materials
- Dear Prescriber Letter
- Dear Pharmacist Letter
- Important Drug Safety Information for Prescribers
- Important Drug Safety Information for Pharmacists
Other Materials
VI. Statutory Elements
This REMS is required under section 505-1 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21-U.S.C. 355-1) and consists of the following elements:
- Medication Guide
- Elements to Assure Safe Use:
- BTODs are dispensed to patients with evidence or other documentation of safe-use conditions under 505-1(f)(3)(D).
- All patients using BTODs are subject to certain monitoring under 505-1(f)(3)(E).
- Implementation System
- Timetable for Submission of Assessments
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 68654759-f50b-79ef-24c5-544d94fe7d87 | Product name | 3 | 20251114 |
| 08a295bb-88df-4ab0-a120-a75a789a74f1 | Product name | 1 | 20231013 |
| ab841ac7-728a-4fc9-be0a-35b96cecbf39 | Product name | 4 | 20230306 |
| 100316cc-94a9-474e-97ad-9b5c6ddec605 | Product name | 5 | 20230125 |
| 539bc5d3-546b-4af6-9c31-058ce6c459d3 | Product name | 2 | 20220210 |
| b871fccd-1de6-4c7f-b9e5-045304641ee6 | Product name | 8 | 20220118 |
| 31e16ab2-c562-4617-a3e8-ed285320e16e | Product name | 1 | 20180201 |
| 4c23a34c-e8fc-424c-8fa0-ee064ba6eaef | Product name | 1 | 20170706 |
| a5920611-4285-f024-69b9-39ff338b81ea | Product name | 5 | 20170609 |
| 3df867ed-9d48-45cf-bded-1394beaea0b1 | Product name | 3 | 20161206 |
| 973da5bf-b1f9-4de0-81ee-7ca066c98ca4 | Product name | 1 | 20160712 |
DailyMed REMS / Drug Safety Documents#
Labels related to this REMS document
Products#
Every source-derived product name is available through these pages.
- Buprenorphine
- Actavis Pharma, Inc.
- American Health Packaging
- buprenorphine hydrochloride
- PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma
- Buprenorphine HCl
- Hikma Pharmaceuticals USA Inc.
- Rhodes Pharmaceuticals L.P.
- Sun Pharmaceutical Industries, Inc.
- Buprenorphine and Naloxone
- Buprenorphine and Naloxone Sublingual Film
- Alvogen Inc.
- Buprenorphine HCl and Naloxone HCl
- Amneal Pharmaceuticals LLC
- Apotex Corp.
- AvPAK
- Dr.Reddys Laboratories Inc
- buprenorphine hydrochloride and naloxone hydrochloride
- Golden State Medical Supply, Inc.
- buprenorphine hydrochloride and naloxone hydrochloride dihydrate
- Suboxone
- buprenorphine hydrochloride, naloxone hydrochloride
- INDIVIOR INC.
- Lannett Company, Inc.
- Mylan Pharmaceuticals Inc.
- Zubsolv
- Orexo US, Inc.
- SpecGx LLC
- Accord Healthcare, Inc
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Buprenorphine | BUPRENORPHINE | REMEDYREPACK INC. | aa86a438-1ebf-4c08-bf27-38f1e81efb3a | 2026-07-07 | Warnings, Adverse reactions | Buprenorphine |
| BUPRENORPHINE | BUPRENORPHINE | Unit Dose Solutions, Inc. | 5578cd5c-c860-6e8a-e063-6394a90a56c7 | 2026-06-30 | Warnings, Adverse reactions | BUPRENORPHINE |
| BUPRENORPHINE | BUPRENORPHINE | Bryant Ranch Prepack | aa132031-9d12-45b4-81e0-4a5877661379 | 2026-06-29 | Warnings, Adverse reactions | BUPRENORPHINE |
| Buprenorphine | BUPRENORPHINE | Bryant Ranch Prepack | 655e3e52-03be-496c-978a-5cffc74b2ae4 | 2026-06-29 | Warnings, Adverse reactions | Buprenorphine |
| BUPRENORPHINE | BUPRENORPHINE | Unit Dose Solutions, Inc. | 5479b218-a388-2c3c-e063-6294a90a0e85 | 2026-06-17 | Warnings, Adverse reactions | BUPRENORPHINE |
| BUPRENORPHINE | BUPRENORPHINE | Bryant Ranch Prepack | 966adb01-71b4-4e0b-bbc6-b83da9987aa2 | 2026-06-16 | Warnings, Adverse reactions | BUPRENORPHINE |
| Buprenorphine | BUPRENORPHINE | Major Pharmaceuticals | dba586f9-e3f2-4b9c-849b-907c81a5a0ef | 2026-06-16 | Warnings, Adverse reactions | Buprenorphine |
| BUPRENORPHINE | BUPRENORPHINE | Bryant Ranch Prepack | bc5a7137-9e8f-438e-84d9-bdbf1db12998 | 2026-06-03 | Warnings, Adverse reactions | BUPRENORPHINE |
| Buprenorphine | BUPRENORPHINE | Rhodes Pharmaceuticals LLC | 2738feae-316e-426f-971c-5f142ac01b60 | 2026-05-29 | Boxed warning, Warnings, Adverse reactions | Buprenorphine |
| Buprenorphine | BUPRENORPHINE | Actavis Pharma, Inc. | 03819118-86f6-4329-adaf-4599e7b71f46 | 2026-05-25 | Warnings, Adverse reactions | Buprenorphine |
| Buprenorphine | BUPRENORPHINE | Teva Pharmaceuticals USA, Inc. | 36995ce3-b515-447b-baa9-aa14f84060d8 | 2026-05-12 | Boxed warning, Warnings, Adverse reactions | Buprenorphine |
| BUPRENORPHINE | BUPRENORPHINE | Rhodes Pharmaceuticals LLC | da90618a-5621-4b15-bc48-9dcc631418de | 2026-05-04 | Warnings, Adverse reactions | BUPRENORPHINE |
| Buprenorphine | BUPRENORPHINE | INGENUS PHARMACEUTICALS, LLC | 186e3be6-8bc0-4bb9-96f5-429d53632f45 | 2026-04-28 | Boxed warning, Warnings, Adverse reactions | Buprenorphine |
| Buprenorphine | BUPRENORPHINE | Aveva Drug Delivery Systems Inc. | 1aae9b13-7431-42ef-8558-14a2325820e6 | 2026-04-28 | Boxed warning, Warnings, Adverse reactions | Buprenorphine |
| BUPRENORPHINE | BUPRENORPHINE | Bryant Ranch Prepack | cd0a90c6-32cc-4114-8573-86ac85503bdf | 2026-04-03 | Warnings, Adverse reactions | BUPRENORPHINE |
| Buprenorphine | BUPRENORPHINE | Sun Pharmaceutical Industries, Inc. | 9fd1f18f-0b0f-4059-b603-19ecbf0ed63a | 2026-02-11 | Warnings, Adverse reactions | Buprenorphine |
| BUPRENORPHINE | BUPRENORPHINE | A-S Medication Solutions | bfb02ea5-22f2-432e-afc8-f1dbe2ea0614 | 2026-02-06 | Warnings, Adverse reactions | BUPRENORPHINE |
| Buprenorphine | BUPRENORPHINE | Hikma Pharmaceuticals USA Inc. | 1bf8b35a-b769-465c-a2f8-099868dfcd2f | 2026-01-24 | Warnings, Adverse reactions | Buprenorphine |
| Buprenorphine | BUPRENORPHINE | Amneal Pharmaceuticals NY LLC | c7d079fb-507f-436f-b794-2171b7d97067 | 2026-01-09 | Boxed warning, Warnings, Adverse reactions | Buprenorphine |
| Buprenorphine | BUPRENORPHINE | AvPAK | 1408cd8f-a0b5-6be7-e063-6394a90a0b41 | 2026-01-08 | Warnings, Adverse reactions | Buprenorphine |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.